Caring Brands shares surge 10.48% intraday after securing exclusive global license for Emesyl, an OTC nausea relief product with $6.23B market potential.

Caring Brands (CABR) surged 10.48% intraday after announcing an exclusive global license to commercialize Emesyl, an over-the-counter nausea relief product. The agreement with Itonis Inc. grants Caring Brands full rights to manufacture, market, and distribute Emesyl, supported by technical and IP data from Itonis. The company highlighted the product’s alignment with its OTC strategy and the $6.23 billion projected market size for nausea treatments in 2025. Terms include future royalty payments and potential equity earn-outs tied to revenue milestones, reinforcing growth potential. The CEO emphasized the strategic importance of expanding the health and wellness portfolio, with plans to launch five new products in two years. The move reflects confidence in leveraging Emesyl’s commercial viability and market demand, directly driving the intraday rally.